Johnson & Johnson (JNJ) Assets Average (2009 - 2026)
Johnson & Johnson (JNJ) posted Assets Average of $200.1 billion for Q1 2026, up 2.06% sequentially from $196.0 billion in Q4 2025, and up 7.04% YoY from $186.9 billion in Q1 2025.
Johnson & Johnson (JNJ) Assets Average (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Assets Average data on file, last reported at $200.1 billion in Q1 2026.
- Quarterly Assets Average rose 7.04% year-over-year to $200.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.1 billion (up 7.04% YoY) and the FY2025 annual result came in at $189.7 billion, up 9.1% from the prior year.
- Assets Average improved to $200.1 billion in Q1 2026 per JNJ's latest filing, from $196.0 billion in the prior quarter.
- The five-year high for Assets Average was $200.1 billion in Q1 2026, with the low at $166.8 billion in Q4 2023.
- Average Assets Average over 5 years is $183.5 billion, with a median of $180.4 billion recorded in 2022.
- Year-over-year, Assets Average slipped 11.43% in 2024 and increased 10.09% in 2025.
- Johnson & Johnson's Assets Average stood at $176.4 billion in 2022, then slipped by 5.45% to $166.8 billion in 2023, then gained by 7.43% to $179.2 billion in 2024, then climbed by 9.39% to $196.0 billion in 2025, then climbed by 2.06% to $200.1 billion in 2026.
- Business Quant data shows JNJ's Assets Average at $200.1 billion in Q1 2026, $196.0 billion in Q4 2025, and $193.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 29.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 200.05 Bn |
| Dec 28, 2025 | 196.01 Bn |
| Sep 28, 2025 | 193.10 Bn |
| Jun 29, 2025 | 193.53 Bn |
| Mar 30, 2025 | 186.89 Bn |
| Dec 29, 2024 | 179.20 Bn |
| Sep 29, 2024 | 179.69 Bn |
| Jun 30, 2024 | 176.53 Bn |
| Mar 31, 2024 | 169.76 Bn |
| Dec 31, 2023 | 166.81 Bn |
| Oct 1, 2023 | 178.87 Bn |
| Jul 2, 2023 | 193.83 Bn |
| Apr 2, 2023 | 191.67 Bn |
| Jan 1, 2023 | 181.25 Bn |
| Oct 2, 2022 | 176.42 Bn |
| Jul 3, 2022 | 178.04 Bn |
| Apr 3, 2022 | 180.19 Bn |
| Jan 2, 2022 | 180.62 Bn |
| Oct 3, 2021 | 177.83 Bn |
| Jul 4, 2021 | 174.50 Bn |